The selected article could not be found. Try again later or contact administrator.
Top Story
Oral anticoagulants REDEEMed? Daily dabigatran "safe" with dual antiplatelets after MI
Nov 19, 2009 11:00 EST
A dose-finding study saw what were characterized as low bleeding rates associated with triple-drug antithrombotic therapy that included the oral anticoagulant dabigatran in patients with a recent ACS event and other cardiovascular risk factors.
Featured news
Medscape Medical News
ALLHAT investigators report 10-year follow-up and stand by diuretics as first step antihypertensive treatment
6 COMMENTS - Nov 19, 2009 14:00 EST
New 10-year mortality and morbidity data confirm the original trial conclusions, they say, that while amlodipine and lisinopril are not superior to chlorthalidone on any outcome, chlorthalidone is superior to these agents on one or more secondary end points. Full agreement with this conclusion in the community, though, is still hard to come by.
News
EFFECT: Public reporting of hospital performance improves quality of care?
Nov 19, 2009 10:00 EST
Publicly released report cards based on hospital performance did not result in a measurably greater systemwide improvement in two composite AMI or CHF process-of-care indicators in a Canadian study. But they did appear to stimulate some important changes in delivery of care that could have led to some better outcomes.
View all »
Editorial series
A series of discussions among editorial leaders, developed by theheart.org

The Cardiology Show
The AHA 2009 Roundup: ARBITER 6-HALTS, PLATO, the two CHAMPIONs, and CASCADE
1 COMMENT - Nov 18, 2009 16:30 EST
Join Drs Valentin Fuster, Roger Blumenthal, Bob Harrington, Judith Hochman, Sanjay Kaul, Suzanne Oparil, Gregg Stone, Lynne Warner Stevenson, and Bruce Wilkoff as they discuss the results of ARBITER 6-HALTS, the PLATO STEMI subanalysis, the two CHAMPIONs, and CASCADE and tackle the issue of too little, too soon in clinical trials today.
Editorial series
New directions for management of patients with atrial fibrillation
Nov 11, 2009 09:50 EST
New agents and interventions are paving the way for revised modalities in the management of patients with atrial fibrillation. Join Drs Alpert and Delascio Lopes for a review of the latest findings and options.
Editorial series
Life and times of leading cardiologists with Rob Califf. Guest: Bob Harrington
3 COMMENTS - Nov 6, 2009 09:50 EST
Raised in a blue-collar neighborhood of Somerville, MA, Dr Bob Harrington was blessed to have a strong family and the Jesuits on his side as he traveled from "Yankee" Boston to Duke University. Join him as he tells his story to Dr Rob Califf.
Editorial series
Clinical research: Comparing regulatory pathways in US and UK
Oct 30, 2009 12:35 EDT
How do regulatory pathways differ in the US and UK? Drs Harrington, Bhatt, and Cleland share their experiences and offer insight on how to support innovative research.
Discussion and opinions
Lively, interactive exchanges moderated by thought leaders, staff or contributors to theheart.org

Topolog
PACE: A trial that challenges dogma
Nov 24, 2009 13:50 EST
This well designed trial sought to find out whether placing a right ventricular lead at the apex--as per standard pacing procedure--leads to adverse cardiac remodeling and hence could promote heart failure and cardiac death.
theheart.org Forum
Discussions among healthcare providers, clinicians, and researchers.
Visit the forum »
Arrhythmia/EP
Hold the epi: No advantage seen with IV drugs at out-of-hospital cardiac arrest
Nov 24, 2009 16:00 EST
The "important and compelling data challenge the efficacy of one of the most common procedures in cardiac resuscitation," says one expert.
Lipid/Metabolic
Vitamin D: A potential role in cardiovascular disease prevention
2 COMMENTS - Nov 24, 2009 14:30 EST
A new observational study shows an association between vitamin D deficiency and cardiovascular disease and death. But definitive data are needed from randomized trials to confirm a beneficial role of this vitamin in CVD prevention, say researchers.
Thrombosis Risk
EINSTEIN-Extension: Rivaroxaban reduces recurrent venous thromboembolism
Nov 24, 2009 13:30 EST
Rivaroxaban reduces recurrent VTE 82% compared with placebo in secondary-prevention patients who completed a course of anticoagulant therapy for the index VTE event.
Lipid/Metabolic
Heart disease evident in mummies 3500 years old
Nov 23, 2009 17:15 EST
Contrary to views that heart disease is the result of modern man's poor lifestyle, new research shows that even ancient Egyptians might have needed a stent or two.
Thrombosis Risk
Postmarketing lessons to learn from Vioxx debacle
Nov 23, 2009 16:00 EST
Data now required by US law could have been put to good use in the Vioxx debacle, helping researchers confirm the cardiovascular risk with the drug much earlier than it was eventually pinpointed, say the authors of a new analysis.
Prevention
Obesity effects on glucose, blood pressure are offsetting gains in smoking status, cholesterol
Nov 23, 2009 15:30 EST
Despite improvements in lowering cholesterol and smoking status over the past 20 years, overall risk-factor profiles in American adults today are identical to those of men and women in the US two decades ago—likely due to rising obesity rates, a new study shows.
News
FDA reports apparent excess of CV events with sibutramine in SCOUT
Nov 23, 2009 14:30 EST
An early analysis for the randomized placebo-controlled trial's primary end point, a composite of cardiovascular events, found a "higher than expected" rate of increase among those getting the appetite suppressant. The trial enrolled a population with a high CV risk, many of whom would not generally be recommended for the drug according to its current labeling.
Medscape Medical News
Stroke incidence related to PCI steady over 15 years
2 COMMENTS - Nov 20, 2009 13:00 EST
Mayo Clinic researchers report that their stroke rate related to PCI has stayed steady for the last 15 years, something they interpret as good news, given that substantially older, sicker patients with more complex anatomy are now undergoing PCI.
Murmurs
Kenneth Baughman killed while jogging at AHA
38 COMMENTS - Nov 19, 2009 08:30 EST
UPDDATED // Dr Kenneth Baughman, a cardiologist at Brigham and Women's Hospital, died Monday morning in Orlando, FL, when he was struck by a car while out for a morning run.
Interventional/Surgery
BARI 2D cost-effectiveness analysis favors medication over PCI for less severe CVD in diabetic patients
1 COMMENT - Nov 18, 2009 15:45 EST
New data from the BARI 2D trial comparing medical therapy vs revascularization in diabetics shows higher up-front costs of revascularization are only partially offset by long-term savings.
Educational partnerships


  • What Happened at CCC 2009?

    A University of Alberta Perspective
    Drs. Armstrong, Ezekowitz, and Welsh as they discuss the latest data to come out of the 2009 sessions of the Canadian Cardiovascular Congress, from Edmonton, Alberta.


  • What Happened at ESC 2009?

    DUKE Heart Center and DUKE Clinical Research Institute
    Drs. Rao, Alexander, Newby, and O'Connor discuss RE-LY, PLATO, and MADIT-CRT.


  • What Happened at ESC 2009?

    Mayo Clinic
    Drs. Gibbons and Jaffe discuss Antiplatelet therapy in ACS, Atrial Fibrillation, Higher dose clopidogrel and aspirin and CRT therapy in patients with Class I or II heart failure.


  • What Happened at HFSA 2009?

    Cleveland Clinic
    Drs. Young, Starling, and Mountis discuss the latest on cardiac resynchronization, ICDs, exercise and heart failure, women in clinical trials, and guidelines.

Most popular
  1. Cardiologists shocked by new FDA alert on clopidogrel-PPI interaction
  2. ACC/AHA focused update of guidelines for STEMI, PCI
  3. Kenneth Baughman killed while jogging at AHA
  4. ALLHAT investigators report 10-year follow-up and stand by diuretics as first step antihypertensive treatment
  5. ARBITER 6-HALTS: HDL raising with niacin superior to ezetimibe
  6. Niacin not beneficial in patients at goal with statins: NIA Plaque
  7. BARI 2D cost-effectiveness analysis favors medication over PCI for less severe CVD in diabetic patients<tab /><tab />
  8. Oral anticoagulants REDEEMed? Daily dabigatran "safe" with dual antiplatelets after MI
  9. Ticagrelor effects unraveled in new phase 2 trials
  10. CT-STAT: CT angiography rules out CAD faster and cheaper than standard care
View all news »
  1. Kenneth Baughman killed while jogging at AHA
  2. ARBITER 6-HALTS: HDL raising with niacin superior to ezetimibe
  3. Niacin not beneficial in patients at goal with statins: NIA Plaque
  4. ACC/AHA focused update of guidelines for STEMI, PCI
  5. CT-STAT: CT angiography rules out CAD faster and cheaper than standard care
  6. 82% reduction in clinical events with combination lipid-lowering therapy (RCT)
  7. ALLHAT investigators report 10-year follow-up and stand by diuretics as first step antihypertensiv
  8. FAIR-HF: Symptom improvement, functional gains follow correction of iron deficiency in heart failu
  9. CASCADE: No significant benefit of clopidogrel in reducing graft disease after CABG
  10. JCHF: Are low doses of carvedilol effective in heart failure?
View all discussions »
button

The Heart of a Woman
Drs. Hayes and Foody and a committee of experts address the gaps and correct the misconception that CVD is more common in men than women.
View all programs »
View all »
Info from Industry
Also on theheart.org
Editorial series
Life and times of leading cardiologists with Rob Califf. Guest: Bob Harrington
3 COMMENTS - Nov 6, 2009 09:50 EST
Raised in a blue-collar neighborhood of Somerville, MA, Dr Bob Harrington was blessed to have a strong family and the Jesuits on his side as he traveled from "Yankee" Boston to Duke University. Join him as he tells his story to Dr Rob Califf.
The Cardiology Show
Best of Barcelona: PLATO and RE-LY
Sep 2, 2009 11:15 EDT
Dr Valentin Fuster returns to the city where he was born for a scintillating discussion with Drs Fox, Gershlick, Marrouche, Messerli, Spaulding, Vergheugt, Virmani, and Yancy about the miracle of RE-LY and the striking success of ticagrelor in the PLATO study.